Evaluation of the Efficacy of Alanyl-Glutamine for Nutritional Support in Septicemia

Objective:To evaluate the therapeutic efficacy of alanyl-glutamine(Ala-Gln)in the nutritional support of sepsis.Methods:120 cases of sepsis patients admitted to the hospital in the past three years were selected and grouped by randomization method,Group A was treated with Ala-Gln,and Group B was treated with conventional nutritional support therapy,and the therapeutic effects were compared.Results:Before treatment,there was no difference in nutritional indexes,immune function indexes,and inflammatory factors between the two groups(P>0.05).After treatment,the nutritional indexes of Group A were higher than those of Group B,the immune function indexes were higher than those of Group B,and the inflammatory factors were lower than those of Group B(P<0.05).Except for mortality,the regression of group A was better than that of group B(P<0.05).Conclusion:Ala-Gln can improve the nutritional indexes of septicemia patients during the treatment period,enhance their immune function,reduce the inflammatory response of the body,and promote the regression of the disease.

Effect of Dietary Alanyl-glutamine Supplementation on Growth Performance, Development of Intestinal Tract, Antioxidant Status and Plasma Non-specific Immunity of Young Mirror Carp(Cyprinus carpio L.)

Exogenous alanyl-glutamine（Aln-Gln） was evaluated for its effects on growth performance, intestinal structure and function, antioxidant status and non-specific immunity of young carp（Cyprinus carpio L.）. Six diets supplemented with 0, 2.5, 5.0, 7.5, 10.0, or 15.0 g · kg-1 of Aln-Gln were fed to fish for 12 weeks. Supplementation with 7.5, 10.0, or 15.0 g · kg-1 of Aln-Gln significantly increased weight gain rate（WGR）, protein efficiency ratio（PER）, but feed conservation rate（FCR） and survival were not affected（P〉0.05）. The intestinal fold height and number, digestive enzyme, Na＋, K＋-ATPase activities was found to be significantly high（P〈0.05） with increasing dietary Aln-Gln supplementation up to 7.5 g · kg-1, but there were no significant differences for Aln-Gln supplementation from 7.5 to 15.0 g · kg-1. The glutathione peroxidase（GPX） activity, glutathione（GSH）, superoxide dismutase（SOD） activity increased and malondialdehyde（MDA） levels decreased significantly（P〈0.05） in the intestine, hepatopancreas, plasma and muscles. The plasma complement-3（C3） and complement-4（C4） levels were significantly（P〈0.05） improved at 5.0 g · kg-1 level and decreased when over 7.5 g · kg-1. The plasma lysozyme（LSZ） activity increased significantly（P〈0.05） at 7.5, 10.0, or 15.0 g · kg-1 level. In summary, the results showed that Aln-Gln improved growth performance, development and function of the intestine, the activity of the antioxidant defense system and the plasma non-specific immunity of the carps. The optimal Aln-Gln level was 8.24 g · kg-1 diet for WGR based on broken-line regression model analysis.

Effects of early enteral nutrition + alanyl-glutamine on intestinal flora, inflammation and oxidative response in patients with SAP

Objective: To investigate the effects of early enteral nutrition + alanyl-glutamine on intestinal flora, inflammation and oxidative response in patients with severe acute pancreatitis (SAP). Methods: A total of 90 patients with SAP who were treated in the hospital between February 2013 and July 2017 were divided into normal EEN group and enhanced EEN group according to different nutritional modes. Normal EEN group received early EEN intervention, and enhanced EEN group received alanyl-glutamine intervention based on early EEN. The differences in the flora distribution in intestinal excreta as well as the contents of inflammatory factors and oxidative stress indexes in serum were compared between the two groups. Results:Before intervention, the differences in the flora distribution in intestinal excreta as well as the contents of inflammatory factors and oxidative stress indexes in serum were not statistically significant between the two groups of patients. After intervention, the bifidobacterium and lactobacillus count in intestinal excreta of enhanced EEN group were higher than those of normal EEN group whereas the enterococcus and escherichia coli count were lower than those of normal EEN group;serum inflammatory cytokines IL-1β, IL-17 and IL-23 contents were lower than those of normal EEN group;serum oxidative stress indexes MPO and XO contents were lower than those of normal EEN group while SOD and CAT contents were higher than those of normal EEN group. Conclusion: EEN combined with alanyl-glutamine therapy can effectively balance the intestinal flora and inhibit the systemic inflammatory response and oxidative stress response in patients with SAP.